Notice of AGM and 2023 UK statutory accounts

Latest News

TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds

TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies

TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies

Upcoming Event

Annual General Meeting of the Shareholders

Latest Financial Results

Q1 2024

Quarter Ended March 31, 2024

Latest Annual Filing

For Fiscal Year Ending December 31, 2023

Company Overview

We are developing safer, less expensive CAR-T products which can target more cancers and save more lives. We do this using our integrated model which drives the development of our products through preclinical testing to the clinic. Our mission is to develop and commercialize innovative cell-based products and to treat disease, improve patient health and Quality of Life.

TC BioPharm (TCBP) is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease.

IR Contacts


TC BioPharm Limited
Maxim 1
2 Parklands Way
Holytown, Motherwell ML1 4WR
United Kingdom
T: +44 (0) 141 433 7557

Investor Relations

Transfer Agent

Computershare Investor Services PLC